The Center for Biosimilars® recaps the top news for the week of March 18, 2019.
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of March 18.
Number 5: Chad Landmon, JD, and Jonathan Knowles, JD, both of Axinn, take a closer look at the FDA’s recently updated guidance on the naming of biosimilars and biologics.
Number 4: In a new research letter, investigators say that, even when generics are available, brands may still receive favorable placement on Part D formularies.
Number 3: In a new paper, researchers reported that although patients had some concerns about safety and efficacy, overall, they were satisfied with the switch to a biosimilar.
Number 2: The Biosimilars Forum and Medicines for Europe released a joint white paper that discusses how Europe has successfully sustained its multisource biosimilars market for the past 10 years.
Number 1: A class action lawsuit has been filed against AbbVie for alleged use of a patent thicket to maintain a monopoly for its brand-name adalimumab, Humira. The complaint also alleges that AbbVie and a number of its biosimilar competitors colluded to divide the market for adalimumab between Europe and the United States.
Finally, last week, our e-newsletter asked whether you think that US health plan sponsors should make greater use of mandatory switching.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.